Cargando…

Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review

BACKGROUND: Immune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological toxicity, especially neutropenia, is rare. CASE...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Qiaoyun, Liu, Lichao, Huang, Yu, Dong, Xiaorong, Chen, Lingjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732564/
https://www.ncbi.nlm.nih.gov/pubmed/36505877
http://dx.doi.org/10.3389/fonc.2022.973421
_version_ 1784846163661291520
author Tan, Qiaoyun
Liu, Lichao
Huang, Yu
Dong, Xiaorong
Chen, Lingjuan
author_facet Tan, Qiaoyun
Liu, Lichao
Huang, Yu
Dong, Xiaorong
Chen, Lingjuan
author_sort Tan, Qiaoyun
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological toxicity, especially neutropenia, is rare. CASE PRESENTATION: A 78-year-old man with squamous lung cancer, with brain metastasis, was treated with pembrolizumab and albumin-bound paclitaxel as first-line treatment for one cycle and changed to pembrolizumab plus anlotinib at the second cycle. After two therapy cycles, grade 4 neutropenia developed, which mainly contributed to irAEs. The patient was started on granulocyte colony-stimulating factor (G-CSF) but did not improve; he was then treated with corticosteroids, and neutrophil counts gradually returned to normal levels. However, the patient eventually died because of neurological problems. CONCLUSION: Grade 4 neutropenia associated with ICI, although rare, is often severe and presents with infectious complications; it needs to be diagnosed early, and clinicians should ensure prompt and proper management to such patients.
format Online
Article
Text
id pubmed-9732564
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97325642022-12-10 Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review Tan, Qiaoyun Liu, Lichao Huang, Yu Dong, Xiaorong Chen, Lingjuan Front Oncol Oncology BACKGROUND: Immune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological toxicity, especially neutropenia, is rare. CASE PRESENTATION: A 78-year-old man with squamous lung cancer, with brain metastasis, was treated with pembrolizumab and albumin-bound paclitaxel as first-line treatment for one cycle and changed to pembrolizumab plus anlotinib at the second cycle. After two therapy cycles, grade 4 neutropenia developed, which mainly contributed to irAEs. The patient was started on granulocyte colony-stimulating factor (G-CSF) but did not improve; he was then treated with corticosteroids, and neutrophil counts gradually returned to normal levels. However, the patient eventually died because of neurological problems. CONCLUSION: Grade 4 neutropenia associated with ICI, although rare, is often severe and presents with infectious complications; it needs to be diagnosed early, and clinicians should ensure prompt and proper management to such patients. Frontiers Media S.A. 2022-11-25 /pmc/articles/PMC9732564/ /pubmed/36505877 http://dx.doi.org/10.3389/fonc.2022.973421 Text en Copyright © 2022 Tan, Liu, Huang, Dong and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tan, Qiaoyun
Liu, Lichao
Huang, Yu
Dong, Xiaorong
Chen, Lingjuan
Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
title Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
title_full Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
title_fullStr Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
title_full_unstemmed Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
title_short Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
title_sort case report: a rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732564/
https://www.ncbi.nlm.nih.gov/pubmed/36505877
http://dx.doi.org/10.3389/fonc.2022.973421
work_keys_str_mv AT tanqiaoyun casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview
AT liulichao casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview
AT huangyu casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview
AT dongxiaorong casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview
AT chenlingjuan casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview